Condition
Warts Hand
Total Trials
6
Recruiting
2
Active
2
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 4 (2)
Trial Status
Completed4
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06791525Phase 4RecruitingPrimary
Tirbanibulin for Pediatric Warts
NCT07448844Phase 4Recruiting
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
NCT05100043CompletedPrimary
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
NCT03487549Phase 2Completed
Cantharidin and Occlusion in Verruca Epithelium
NCT04738734Not ApplicableCompleted
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
NCT04554394Not ApplicableCompleted
CellFX System for the Treatment of Cutaneous Non-Genital Warts
Showing all 6 trials